검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) + ibrutinib, lisocabtagene maraleucel) Bristol Myers Squibb·Leukemia, Lymphocytic, Chronic, B-… ORR 80.5% |
|---|---|
Overview Program | JCAR017 (lisocabtagene maraleucel) + ibrutinib |
Overview Company | Bristol Myers Squibb |
Overview Modality | CGT |
Overview Target | Leukemia, Lymphocytic, Chronic, B-Cell |
Overview Indication | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | CAR T-cell patients is largely dependent on institutional experience |
MoA Biomarker | biomarker that predicts delayed humoral immune recovery, increased infectious events, and treatment-related m |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.. In TRANSCEND FL, lisocabtagene maraleucel (liso-cel) demonstrated strong efficacy, with 97% overall response rate (ORR) and 94% complete response (CR) rate in third-line or later (3 L+) follicular lymphoma (FL). Here, we compared efficacy and sa… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 80.5% |
Clinical ORR | 53.7% |
Clinical PFS | 5.86 |
Clinical OS | 21.88 |
Clinical Result source | ClinicalTrials.gov NCT03744676 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) + ibrutinib, lisocabtagene maraleucel) Bristol Myers Squibb·Leukemia, Lymphocytic, Chronic, B-… ORR 80.5% |
|---|---|
Overview Program | JCAR017 (lisocabtagene maraleucel) + ibrutinib |
Overview Company | Bristol Myers Squibb |
Overview Modality | CGT |
Overview Target | Leukemia, Lymphocytic, Chronic, B-Cell |
Overview Indication | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | CAR T-cell patients is largely dependent on institutional experience |
MoA Biomarker | biomarker that predicts delayed humoral immune recovery, increased infectious events, and treatment-related m |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.. In TRANSCEND FL, lisocabtagene maraleucel (liso-cel) demonstrated strong efficacy, with 97% overall response rate (ORR) and 94% complete response (CR) rate in third-line or later (3 L+) follicular lymphoma (FL). Here, we compared efficacy and sa… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 80.5% |
Clinical ORR | 53.7% |
Clinical PFS | 5.86 |
Clinical OS | 21.88 |
Clinical Result source | ClinicalTrials.gov NCT03744676 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교